What genetics tells us about the causes and mechanisms of Parkinson's disease.
暂无分享,去创建一个
[1] A. Singleton,et al. Analysis of an early‐onset Parkinson's disease cohort for DJ‐1 mutations , 2004, Movement disorders : official journal of the Movement Disorder Society.
[2] Angela C. Poole,et al. The PINK1/Parkin pathway regulates mitochondrial morphology , 2008, Proceedings of the National Academy of Sciences.
[3] L. Meijer,et al. Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.
[4] M. Mattson,et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism , 2002, Annals of neurology.
[5] M. Polymeropoulos,et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients , 2000, Neuroreport.
[6] R. Nussbaum,et al. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6 , 2007, Neurobiology of Disease.
[7] M. Mena,et al. Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis , 2009, Journal of neurochemistry.
[8] M. Farrer,et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. , 2001, Archives of neurology.
[9] H. Sandoval,et al. Essential role for Nix in autophagic maturation of erythroid cells , 2008, Nature.
[10] Jie Shen,et al. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress , 2008, Proceedings of the National Academy of Sciences.
[11] J. Schulz,et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. , 2005, Human molecular genetics.
[12] R. Köster,et al. Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). , 2009, Brain : a journal of neurology.
[13] D. Hernandez,et al. Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[14] G. Dekomien,et al. Parkin gene variations in late‐onset Parkinson's disease: comparison between Norwegian and German cohorts , 2006, Acta neurologica Scandinavica.
[15] Isao Nishimura,et al. Parkin Suppresses Dopaminergic Neuron-Selective Neurotoxicity Induced by Pael-R in Drosophila , 2003, Neuron.
[16] M. Ueffing,et al. The Parkinson disease‐associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro , 2009, Journal of neurochemistry.
[17] Sebastian Brandner,et al. Neuroprotective Role of the Reaper-Related Serine Protease HtrA2/Omi Revealed by Targeted Deletion in Mice , 2004, Molecular and Cellular Biology.
[18] B. Oostra,et al. The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population , 2008, Neurogenetics.
[19] A. Brice,et al. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function , 2005, Journal of neurochemistry.
[20] Yu Kyeong Kim,et al. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. , 2007, Archives of neurology.
[21] N. Wood,et al. PINK1 function in health and disease , 2009, EMBO molecular medicine.
[22] Patrik Brundin,et al. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.
[23] D. D. De Silva,et al. PINK1 mutations in sporadic early‐onset Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[24] J. Nutt,et al. SCA2 may present as levodopa‐responsive parkinsonism , 2003, Movement disorders : official journal of the Movement Disorder Society.
[25] M. Ronaghi,et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. , 2008, American journal of human genetics.
[26] K. Jellinger,et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.
[27] C. Sander,et al. Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies , 2010, Nature Genetics.
[28] K. Marder,et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease , 2006, Neurology.
[29] E. Masliah,et al. Phosphorylation of Synucleins by Members of the Polo-like Kinase Family* , 2009, The Journal of Biological Chemistry.
[30] D. Maraganore,et al. A Genomic Pathway Approach to a Complex Disease: Axon Guidance and Parkinson Disease , 2007, PLoS genetics.
[31] Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation , 2005, Neurology.
[32] A. Quattrone,et al. Compound heterozygosity in DJ-1 gene non-coding portion related to parkinsonism. , 2009, Parkinsonism & related disorders.
[33] A. Deutch,et al. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration , 2007, Brain Research.
[34] Yan Liu,et al. LRRK2 R1628P contributes to Parkinson's disease susceptibility in Chinese Han populations from mainland China , 2009, Brain Research.
[35] A. Brice,et al. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. , 2006, Human molecular genetics.
[36] A. Bentivoglio,et al. Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinsonian patients , 2007, Movement disorders : official journal of the Movement Disorder Society.
[37] A. Brice,et al. α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.
[38] P. Stanzione,et al. Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[39] V. Hristova,et al. Identification of a Novel Zn2+-binding Domain in the Autosomal Recessive Juvenile Parkinson-related E3 Ligase Parkin* , 2009, Journal of Biological Chemistry.
[40] Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein , 2008 .
[41] J. Jankovic,et al. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. , 2008, Parkinsonism & related disorders.
[42] D. Price,et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. , 2006, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[43] H. Fung,et al. The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease. , 2008, Archives of Neurology.
[44] G. Hadjigeorgiou,et al. Mutated α-synuclein gene in two Greek kindreds with familial PD: Incomplete penetrance? , 1999, Neurology.
[45] B. E. Staveley,et al. Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease. , 2006, Genome.
[46] L. Stefanis,et al. Proteasomal Inhibition-Induced Inclusion Formation and Death in Cortical Neurons Require Transcription and Ubiquitination , 2002, Molecular and Cellular Neuroscience.
[47] N. Ip,et al. The emerging role of autophagy in Parkinson's disease , 2009, Molecular Brain.
[48] M. MacDonald,et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. , 2002, American journal of human genetics.
[49] A. Mubaidin,et al. Pallido‐pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor‐Rakeb syndrome , 1994, Acta neurologica Scandinavica.
[50] L. Chin,et al. Ubiquitination of α-synuclein by Siah-1 promotes α-synuclein aggregation and apoptotic cell death , 2007 .
[51] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[52] E. Tolosa,et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.
[53] N. Hattori,et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy , 2010, The Journal of cell biology.
[54] S. Itohara,et al. Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. , 2007, Human molecular genetics.
[55] N. Thakor,et al. Parkin Facilitates the Elimination of Expanded Polyglutamine Proteins and Leads to Preservation of Proteasome Function* , 2003, Journal of Biological Chemistry.
[56] A. Ishikawa,et al. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism , 1996, Neurology.
[57] Mark Guttman,et al. Brain proteasomal function in sporadic Parkinson's disease and related disorders , 2002, Annals of neurology.
[58] Ivan Dikic,et al. Atypical ubiquitin chains: new molecular signals , 2008, EMBO reports.
[59] Nir Giladi,et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease , 2007, Neurology.
[60] James Lowe,et al. Depletion of 26S Proteasomes in Mouse Brain Neurons Causes Neurodegeneration and Lewy-Like Inclusions Resembling Human Pale Bodies , 2008, The Journal of Neuroscience.
[61] Ann Saada,et al. The Transgenic Overexpression of α-Synuclein and Not Its Related Pathology Associates with Complex I Inhibition* , 2010, The Journal of Biological Chemistry.
[62] P. Pástor,et al. PINK1-linked parkinsonism is associated with Lewy body pathology. , 2010, Brain : a journal of neurology.
[63] P. Pramstaller,et al. Association studies of Parkinson's disease and parkin polymorphisms , 2000, Annals of neurology.
[64] E. Masliah,et al. Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions , 2010, The Journal of Neuroscience.
[65] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[66] G. Halliday,et al. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. , 2001, Annals of neurology.
[67] K. Lim,et al. Jcb: Report , 2022 .
[68] C. Lautier,et al. GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling. , 2009, Human molecular genetics.
[69] C. Chu,et al. Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. , 2009, Mitochondrion.
[70] Ted M. Dawson,et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy , 2009, Proceedings of the National Academy of Sciences.
[71] N. Hattori,et al. Mutation analysis for DJ-1 in sporadic and familial parkinsonism: Screening strategy in parkinsonism , 2009, Neuroscience Letters.
[72] Yi Zhao,et al. Genetic analysis of SCA2, 3 and 17 in idiopathic Parkinson's disease , 2006, Neuroscience Letters.
[73] M. Riparbelli,et al. The Drosophila parkin homologue is required for normal mitochondrial dynamics during spermiogenesis. , 2007, Developmental biology.
[74] M. Vidailhet,et al. LOW DISEASE RISK IN RELATIVES OF NORTH AFRICAN LRRK2 PARKINSON DISEASE PATIENTS , 2010, Neurology.
[75] W. Bender,et al. A Drosophila model of Parkinson's disease , 2000, Nature.
[76] A. Parent,et al. Parkin immunoreactivity in the brain of human and non‐human primates: An immunohistochemical analysis in normal conditions and in Parkinsonian syndromes , 2001, The Journal of comparative neurology.
[77] Wei Jiang,et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. , 2009, The Journal of clinical investigation.
[78] A. Singleton,et al. Clinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease , 2006 .
[79] O. Sydow,et al. S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden. , 2007, Parkinsonism & related disorders.
[80] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[81] W. Parker,et al. Creation and Characterization of Mitochondrial DNA‐Depleted Cell Lines with “Neuronal‐Like” Properties , 1996, Journal of neurochemistry.
[82] H. Tanila,et al. Role of alpha-synuclein in presynaptic dopamine recruitment. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[83] M. Beal,et al. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery , 2008, Proceedings of the National Academy of Sciences.
[84] T. Meitinger,et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.
[85] L. Forno,et al. Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.
[86] J. Obeso,et al. Analysis of the GIGYF2 gene in familial and sporadic Parkinson disease in the Spanish population , 2010, European journal of neurology.
[87] M. Rapé,et al. Building ubiquitin chains: E2 enzymes at work , 2009, Nature Reviews Molecular Cell Biology.
[88] M. Farrer,et al. Lrrk2 pathogenic substitutions in Parkinson's disease , 2005, Neurogenetics.
[89] Mariza de Andrade,et al. High-resolution whole-genome association study of Parkinson disease. , 2005, American journal of human genetics.
[90] N. Hattori,et al. Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier , 2007, Journal of the Neurological Sciences.
[91] A Dürr,et al. Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[92] J. Langston,et al. 1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra , 1984, Neuroscience Letters.
[93] M. Canesi,et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor , 2005, Journal of Medical Genetics.
[94] Li Chen,et al. α-Synuclein and Parkin Contribute to the Assembly of Ubiquitin Lysine 63-linked Multiubiquitin Chains* , 2005, Journal of Biological Chemistry.
[95] A. Singleton,et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. , 2005, Brain : a journal of neurology.
[96] N. Hattori,et al. Neuropsychiatric and cognitive features in autosomal‐recessive early parkinsonism due to PINK1 mutations , 2007, Movement disorders : official journal of the Movement Disorder Society.
[97] A. Singleton,et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. , 2006, Annals of neurology.
[98] Peter T Lansbury,et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. , 2008, The Journal of clinical investigation.
[99] R. Krüger,et al. Familial parkinsonism with synuclein pathology , 2001, Neurology.
[100] P. Lichtner,et al. PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. , 2009, Parkinsonism & related disorders.
[101] A. Reichert,et al. Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin , 2007, The Journal of Neuroscience.
[102] J. Burgunder,et al. LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han‐Chinese from mainland China , 2008, European journal of neurology.
[103] Susan Lindquist,et al. Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein , 2003, Science.
[104] P. Emson,et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain , 2006, Annals of neurology.
[105] A. Graybiel,et al. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.
[106] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[107] Jian Feng,et al. Parkin Increases Dopamine Uptake by Enhancing the Cell Surface Expression of Dopamine Transporter* , 2004, Journal of Biological Chemistry.
[108] A. Singleton,et al. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan , 2006, BMC neurology.
[109] Harry T Orr,et al. Trinucleotide repeat disorders. , 2007, Annual review of neuroscience.
[110] N. Hattori,et al. Parkin stabilizes PINK1 through direct interaction. , 2009, Biochemical and biophysical research communications.
[111] R. P. Maguire,et al. Familial parkinsonism with synuclein pathology: Clinical and PET studies of A30P mutation carriers , 2001 .
[112] J. Hardy,et al. The genetics of Parkinson's syndromes: a critical review. , 2009, Current opinion in genetics & development.
[113] David W. Miller,et al. Mitochondrial Alterations in PINK1 Deficient Cells Are Influenced by Calcineurin-Dependent Dephosphorylation of Dynamin-Related Protein 1 , 2009, PloS one.
[114] J. Vicencio,et al. Ca2+, autophagy and protein degradation: thrown off balance in neurodegenerative disease. , 2010, Cell calcium.
[115] R. Marconi,et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease , 2006, European Journal of Human Genetics.
[116] E. Friedman,et al. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation , 2009, Journal of Neurology.
[117] P. Deyn,et al. GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population , 2011, Neurobiology of Aging.
[118] Y. Agid,et al. A multidisciplinary study of patients with early-onset PD with and without parkin mutations , 2009, Neurology.
[119] R. Barker,et al. A case of late onset sporadic Parkinson’s disease with an A53T mutation in α-synuclein , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[120] D. Sulzer,et al. Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.
[121] R. Barbour,et al. Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.
[122] Alexandra Durr,et al. How much phenotypic variation can be attributed to parkin genotype? , 2003, Annals of neurology.
[123] Yuliang Wu,et al. Direct binding of α‐actinin enhances TRPP3 channel activity , 2007 .
[124] S. Lindquist,et al. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. , 2003, Science.
[125] G. Zeevalk,et al. Glutathione and Parkinson's disease: is this the elephant in the room? , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[126] David F. Clayton,et al. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.
[127] E. Masliah,et al. α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.
[128] P. Heutink,et al. Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6 , 2010, Cell Death and Differentiation.
[129] Matthew J. Farrer,et al. LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.
[130] D W Dickson,et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology , 2004, Neurology.
[131] T. Niki,et al. DJ‐1 has a role in antioxidative stress to prevent cell death , 2004, EMBO reports.
[132] Mohamad Saad,et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.
[133] A. Whitworth,et al. Drosophila Parkin requires PINK1 for mitochondrial translocation and ubiquitinates Mitofusin , 2010, Proceedings of the National Academy of Sciences.
[134] A. Bentivoglio,et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. , 2001, American journal of human genetics.
[135] D. Turnbull,et al. MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE , 1989, The Lancet.
[136] R. S. Burns,et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.
[137] M. Iwata,et al. Parkin-positive autosomal recessive juvenile parkinsonism with α-synuclein-positive inclusions , 2004, Neurology.
[138] P. Blain,et al. Mitochondrial Dysfunction in Parkinson's Disease , 2011, Parkinson's disease.
[139] A. Lees,et al. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress , 2006, Journal of neurochemistry.
[140] S. Yazawa,et al. Familial Parkinsonism with digenic parkin and PINK1 mutations , 2008, Movement disorders : official journal of the Movement Disorder Society.
[141] C. Ross,et al. Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation , 2005, The Journal of Neuroscience.
[142] H Okazaki,et al. Hereditary form of parkinsonism—dementia , 1998, Annals of neurology.
[143] J. Cooper,et al. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons , 2006, Annals of neurology.
[144] A. Dahlström,et al. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. , 2002, Neuroscience.
[145] I. König,et al. Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[146] C. Ki,et al. The Ala53Thr mutation in the α‐synuclein gene in a Korean family with Parkinson disease , 2007 .
[147] Fabienne C. Fiesel,et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 , 2010, Nature Cell Biology.
[148] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[149] Y. Yoon,et al. Perturbations in Mitochondrial Dynamics Induced by Human Mutant PINK1 Can Be Rescued by the Mitochondrial Division Inhibitor mdivi-1* , 2010, The Journal of Biological Chemistry.
[150] T. Hashikawa,et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. , 2002, Molecular cell.
[151] Roya Saffary,et al. Inclusion Body Formation and Neurodegeneration Are Parkin Independent in a Mouse Model of α-Synucleinopathy , 2006, The Journal of Neuroscience.
[152] Yih-Ru Wu,et al. Lrrk2 R1628P in non‐Chinese Asian races , 2008, Annals of neurology.
[153] C. Culmsee,et al. Parkin Mediates Neuroprotection through Activation of IκB Kinase/Nuclear Factor-κB Signaling , 2007, The Journal of Neuroscience.
[154] David W. Miller,et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[155] Y. Mizuno,et al. Clinical, pathologic and genetic studies on autosomal recessive early-onset parkinsonism with diurnal fluctuation. , 1998, Parkinsonism & related disorders.
[156] J Q Trojanowski,et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.
[157] A. Brice,et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K–Akt signalling , 2006, Nature Cell Biology.
[158] J. Menéndez,et al. Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity , 2006, Neuropharmacology.
[159] J. Jankovic,et al. GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients , 2009, Neuroscience Letters.
[160] R. Pfeiffer,et al. A Greek‐American kindred with autosomal dominant, levodopa‐responsive parkinsonism and anticipation , 1995, Annals of neurology.
[161] J. Nutt,et al. Genetic association between α‐synuclein and idiopathic parkinson's disease , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[162] M. Farrer,et al. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s disease , 1999, Neurology.
[163] K. Marder,et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations , 2009, Neurology.
[164] V. Bader,et al. Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. , 2007, Human molecular genetics.
[165] G. Hadjigeorgiou,et al. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? , 1999, Neurology.
[166] M. Farrer,et al. Reported mutations in GIGYF2 are not a common cause of Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[167] N. Hattori,et al. Parkin Cleaves Intracellular α-Synuclein Inclusions via the Activation of Calpain* , 2003, Journal of Biological Chemistry.
[168] J. Trojanowski,et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. , 2003, Biochemistry.
[169] Stéphane Thobois,et al. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. , 2006, Brain : a journal of neurology.
[170] Wenbo Zhou,et al. DJ-1 Up-regulates Glutathione Synthesis during Oxidative Stress and Inhibits A53T α-Synuclein Toxicity* , 2005, Journal of Biological Chemistry.
[171] A. Dahlström,et al. Differential localization of α-, β- and γ-synucleins in the rat CNS , 2002, Neuroscience.
[172] A. Whitworth,et al. Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin , 2009, Cell Death and Differentiation.
[173] G. Seidel,et al. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles , 2007, Journal of Neurology.
[174] R. Baggott. DISEASE , 1947, Social Policy & Administration.
[175] D. Selkoe,et al. Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.
[176] J. Trojanowski,et al. Biochemical and pathological characterization of Lrrk2 , 2006, Annals of neurology.
[177] Gwang Lee,et al. Molecular interaction between parkin and PINK1 in mammalian neuronal cells , 2009, Molecular and Cellular Neuroscience.
[178] J. Haines,et al. Parkin mutations and susceptibility alleles in late‐onset Parkinson's disease , 2003, Annals of neurology.
[179] J. C. Greene,et al. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[180] N. Bonini,et al. DJ‐1 is present in a large molecular complex in human brain tissue and interacts with α‐synuclein , 2005, Journal of neurochemistry.
[181] B. Hyman,et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. , 2002, The American journal of pathology.
[182] B. E. Staveley,et al. Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson's disease. , 2008, Genome.
[183] M. Farrer,et al. Parkin variants in North American Parkinson's disease: Cases and controls , 2003, Movement disorders : official journal of the Movement Disorder Society.
[184] M. Farrer,et al. Clinical characteristics of Parkinson’s disease among Jewish Ethnic groups in Israel , 2008, Journal of Neural Transmission.
[185] T. Foroud,et al. Mutations in DJ-1 are rare in familial Parkinson disease , 2006, Neuroscience Letters.
[186] J. Trojanowski,et al. Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* , 2002, The Journal of Biological Chemistry.
[187] A. Schapira. Future directions in the treatment of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[188] C. Duyckaerts,et al. Leucine-Rich Repeat Kinase 2 Is Associated With the Endoplasmic Reticulum in Dopaminergic Neurons and Accumulates in the Core of Lewy Bodies in Parkinson Disease , 2010, Journal of neuropathology and experimental neurology.
[189] Ren-Shyan Liu,et al. Presence of spinocerebellar ataxia type 2 gene mutation in a patient with apparently sporadic Parkinson's disease: Clinical implications , 2004, Movement disorders : official journal of the Movement Disorder Society.
[190] K. Lohmann,et al. Genetic association study of the P‐type ATPase ATP13A2 in late‐onset Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[191] A. Singleton,et al. Screening for LRRK2 mutations in patients with Parkinson’s disease in Russia: identification of a novel LRRK2 variant , 2008, European journal of neurology.
[192] N. Hattori,et al. An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.
[193] H. Shill,et al. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study , 2008, BMC medicine.
[194] J. Growdon,et al. A haplotype at the PARK3 locus influences onset age for Parkinson’s disease , 2003, Neurology.
[195] E. Hirsch,et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. , 2003, Human molecular genetics.
[196] Erika K Wallender,et al. Optical Reporters for the Conformation of α-Synuclein Reveal a Specific Interaction with Mitochondria , 2008, The Journal of Neuroscience.
[197] C. Olanow,et al. Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants , 2007, Journal of neurochemistry.
[198] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[199] R. Krüger,et al. Reduced Basal Autophagy and Impaired Mitochondrial Dynamics Due to Loss of Parkinson's Disease-Associated Protein DJ-1 , 2010, PloS one.
[200] David S. Park,et al. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP , 2008, Proceedings of the National Academy of Sciences.
[201] P. Pollak,et al. Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans. , 2010, Human molecular genetics.
[202] T. Foroud,et al. Variation in GIGYF2 is not associated with Parkinson disease , 2009, Neurology.
[203] E. Masliah,et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.
[204] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[205] M. Cookson,et al. The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation* , 2008, Journal of Biological Chemistry.
[206] C. Duyckaerts,et al. Parkin Deficiency Delays Motor Decline and Disease Manifestation in a Mouse Model of Synucleinopathy , 2009, PloS one.
[207] Bryan L Roth,et al. Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons* , 2003, Journal of Biological Chemistry.
[208] F. Binkofski,et al. ATP13A2 variants in early‐onset Parkinson's disease patients and controls , 2009, Movement disorders : official journal of the Movement Disorder Society.
[209] O. Bandmann,et al. p53‐dependent neuronal cell death in a DJ‐1‐deficient zebrafish model of Parkinson's disease , 2006, Journal of neurochemistry.
[210] P. Axelsen,et al. Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† , 2003 .
[211] J. Kordower,et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys , 2006, Annals of neurology.
[212] J. Rothwell,et al. Motor cortical physiology in patients and asymptomatic carriers of parkin gene mutations , 2008, Movement disorders : official journal of the Movement Disorder Society.
[213] Peter K. Kim,et al. Mitochondria Supply Membranes for Autophagosome Biogenesis during Starvation , 2010, Cell.
[214] W. Oyen,et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome , 2009, Neurology.
[215] Leonidas Stefanis,et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.
[216] Hansong Deng,et al. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila , 2008, Proceedings of the National Academy of Sciences.
[217] A. Singleton,et al. Parkinson's disease due to the R1441G mutation in Dardarin: A founder effect in the basques , 2006, Movement disorders : official journal of the Movement Disorder Society.
[218] C. Lautier,et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. , 2008, American journal of human genetics.
[219] S. Lindquist,et al. α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.
[220] Penny A. MacDonald,et al. Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. , 2007, Molecular biology of the cell.
[221] Asunción Delgado,et al. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. , 2007, Human molecular genetics.
[222] Patrick M. Abou-Sleiman,et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease , 2009, Nature Cell Biology.
[223] A. Singleton,et al. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort , 2005, Movement disorders : official journal of the Movement Disorder Society.
[224] C. Ross,et al. Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.
[225] M. Augustin,et al. Parkin expression in the adult mouse brain , 2000, The European journal of neuroscience.
[226] A. Mosley,et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations , 2005, Neurology.
[227] Michael R. Duchen,et al. PINK1-Associated Parkinson's Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death , 2009, Molecular cell.
[228] H. Cai,et al. Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein , 2009, Neuron.
[229] P. Remy,et al. Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration , 2011, Neurobiology of Aging.
[230] M. Spillantini,et al. α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome , 2001, FEBS letters.
[231] R. Nussbaum,et al. Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration , 2009, PloS one.
[232] P. S. St George-Hyslop,et al. Wild-type PINK1 Prevents Basal and Induced Neuronal Apoptosis, a Protective Effect Abrogated by Parkinson Disease-related Mutations* , 2005, Journal of Biological Chemistry.
[233] David S. Park,et al. Loss of PINK1 Function Promotes Mitophagy through Effects on Oxidative Stress and Mitochondrial Fission* , 2009, Journal of Biological Chemistry.
[234] M. Farrer,et al. α‐Synuclein promoter confers susceptibility to Parkinson's disease , 2004 .
[235] C. Marsden,et al. A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.
[236] William Lin,et al. Characterization of PINK1 processing, stability, and subcellular localization , 2008, Journal of neurochemistry.
[237] T. Mitsui,et al. Parkin enhances mitochondrial biogenesis in proliferating cells. , 2006, Human molecular genetics.
[238] J. Trojanowski,et al. Concurrence of α-synuclein and tau brain pathology in the Contursi kindred , 2002, Acta Neuropathologica.
[239] N. Avadhani,et al. Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.
[240] Jian Feng,et al. Parkin Protects Dopaminergic Neurons against Microtubule-depolymerizing Toxins by Attenuating Microtubule-associated Protein Kinase Activation* , 2009, Journal of Biological Chemistry.
[241] Tatiana Foroud,et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease , 2005, The Lancet.
[242] Matthew J. Farrer,et al. α-synuclein gene haplotypes are associated with Parkinson’s disease , 2001 .
[243] Ming Zhan,et al. RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways , 2008, Proceedings of the National Academy of Sciences.
[244] J. Ahlskog. Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. , 2009, Parkinsonism & related disorders.
[245] Y. Teo,et al. Alpha-synuclein haplotypes implicated in risk of Parkinson’s disease , 2004, Neurology.
[246] Marc Cruts,et al. Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update , 2010, Human mutation.
[247] A. Pisani,et al. Impaired dopamine release and synaptic plasticity in the striatum of Parkin−/− mice , 2009, Journal of neurochemistry.
[248] G. Opala,et al. Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease , 2005, Neuroscience Letters.
[249] P. Lansbury,et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[250] J. Aharon-Peretz,et al. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2004, The New England journal of medicine.
[251] Christine Klein,et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.
[252] Eden R Martin,et al. Genome-wide linkage screen in familial Parkinson disease identifies loci on chromosomes 3 and 18. , 2009, American journal of human genetics.
[253] V. Emmel,et al. Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions. , 2009, Parkinsonism & related disorders.
[254] Shu G. Chen,et al. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. , 2007, Experimental cell research.
[255] Nobutaka Hattori,et al. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. , 2005, Parkinsonism & related disorders.
[256] H. McBride. Parkin mitochondria in the autophagosome , 2008, The Journal of cell biology.
[257] P. Kolatkar,et al. The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence , 2006, Human Genetics.
[258] P. Lansbury,et al. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. , 2007, Biochemistry.
[259] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[260] A. Bentivoglio,et al. PINK1 mutations are associated with sporadic early‐onset parkinsonism , 2004, Annals of neurology.
[261] R. Nussbaum,et al. Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. , 2008, Experimental cell research.
[262] P. V. van Haastert,et al. Roc, a Ras/GTPase domain in complex proteins. , 2003, Biochimica et biophysica acta.
[263] F. Checler,et al. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. , 2002, The Journal of biological chemistry.
[264] Atsushi Tanaka,et al. PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.
[265] P. Pollak,et al. Multifocal enhancing cortical lesions in a patient with Churg-Strauss syndrome , 2008, Neurology.
[266] Z. Wszolek,et al. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. , 2009, Parkinsonism & related disorders.
[267] M. Farrer,et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.
[268] J. Trojanowski,et al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. , 2002, The Journal of biological chemistry.
[269] J. Trojanowski,et al. Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. , 2002, Neurotoxicology.
[270] T. Katada,et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. , 2007, Biochemistry.
[271] E. Tan,et al. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease , 2008, Journal of neuroscience research.
[272] B. Giasson,et al. DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity. , 2010, Human molecular genetics.
[273] M. Farrer,et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease , 2008, Annals of neurology.
[274] Bertram Müller-Myhsok,et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. , 2004, American journal of human genetics.
[275] Matthew J. Farrer,et al. Digenic parkinsonism: Investigation of the synergistic effects of PRKN and LRRK2 , 2006, Neuroscience Letters.
[276] G. Schellenberg,et al. LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[277] P. Lansbury,et al. Membrane-associated farnesylated UCH-L1 promotes α-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease , 2009, Proceedings of the National Academy of Sciences.
[278] R. Youle,et al. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL , 2010, The Journal of cell biology.
[279] A. Bonnet,et al. A-SYNUCLEIN GENE DUPLICATION IS PRESENT IN SPORADIC PARKINSON DISEASE. Authors' reply , 2008 .
[280] R. Marconi,et al. GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. , 2009, Parkinsonism & related disorders.
[281] D. Eliezer,et al. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated α-Synuclein , 2004 .
[282] K. Moore,et al. Induction of the Phase II Detoxification Pathway Suppresses Neuron Loss in Drosophila Models of Parkinson's Disease , 2008, The Journal of Neuroscience.
[283] E. Sidransky,et al. Glucocerebrosidase mutations in subjects with parkinsonism. , 2004, Molecular genetics and metabolism.
[284] C. Olanow,et al. Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease , 2002, Neuroscience Letters.
[285] G. Schellenberg,et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. , 2008, Archives of neurology.
[286] S. Kuno,et al. Cytoplasmic transfer of platelet mtDNA from elderly patients with Parkinson's disease to mtDNA-less HeLa cells restores complete mitochondrial respiratory function. , 2001, Biochemical and biophysical research communications.
[287] K. Marder,et al. Frequency of parkin mutations in late‐onset Parkinson's disease , 2003, Annals of neurology.
[288] A. Landau,et al. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle , 2007, Movement disorders : official journal of the Movement Disorder Society.
[289] Robert Hill,et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.
[290] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[291] M. Farrer,et al. Glucosidase-beta variations and Lewy body disorders. , 2009, Parkinsonism & related disorders.
[292] M. Cookson,et al. Genetic neuropathology of Parkinson's disease. , 2008, International journal of clinical and experimental pathology.
[293] Biao Chen,et al. ACT and UCH‐L1 polymorphisms in Parkinson's disease and age of onset , 2002, Movement disorders : official journal of the Movement Disorder Society.
[294] E. Masliah,et al. alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease. , 2008, The Journal of biological chemistry.
[295] K. Doheny,et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.
[296] C. Marsden,et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.
[297] Li Zhang,et al. A missense mutation (L166P) in DJ‐1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo‐oligomerization , 2003, Journal of neurochemistry.
[298] S. Choudhry,et al. CAG repeat instability at SCA2 locus: anchoring CAA interruptions and linked single nucleotide polymorphisms. , 2001, Human molecular genetics.
[299] Glenda M. Halliday,et al. Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation , 2001 .
[300] P. McPherson,et al. SH3 domains from a subset of BAR proteins define a Ubl-binding domain and implicate parkin in synaptic ubiquitination. , 2009, Molecular cell.
[301] A. Brice,et al. Of Parkin and Parkinson's: light and dark sides of a multifaceted E3 ubiquitin–protein ligase , 2007 .
[302] P. Aebischer,et al. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[303] M. Cookson,et al. Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.
[304] M. Cookson,et al. Parkinson's disease: insights from pathways. , 2010, Human molecular genetics.
[305] Jeremy N. Skepper,et al. α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.
[306] R. Mandel,et al. The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease , 2008, Proceedings of the National Academy of Sciences.
[307] Bonifati,et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. , 2000, The New England journal of medicine.
[308] Matthew J. Farrer,et al. Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .
[309] P. Amouyel,et al. S18Y polymorphism in the UCH‐L1 gene and Parkinson's disease: Evidence for an age‐dependent relationship , 2003, Movement disorders : official journal of the Movement Disorder Society.
[310] D. Berg,et al. Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. , 2009, Human molecular genetics.
[311] Jin Man Kim,et al. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[312] M. Farrer,et al. PARK11 is not linked with Parkinson's disease in European families , 2005, European Journal of Human Genetics.
[313] Christian Haass,et al. Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. , 2002, Journal of neurochemistry.
[314] L. Chin,et al. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. , 2008, Human molecular genetics.
[315] L. Meijer,et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. , 2000, The Journal of biological chemistry.
[316] R. Krüger,et al. Haploinsufficiency at the α‐synuclein gene underlies phenotypic severity in familial Parkinson’s disease , 2003 .
[317] J. Parks,et al. Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.
[318] M. Feany,et al. α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.
[319] Yi Zhao,et al. Case–control study of UCHL1 S18Y variant in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[320] M. Farrer,et al. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. , 2006, Archives of neurology.
[321] K. Xia,et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. , 2006, Human molecular genetics.
[322] A. Kakita,et al. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. , 2008, Archives of neurology.
[323] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[324] E. Masliah,et al. β-Synuclein Displays an Antiapoptotic p53-dependent Phenotype and Protects Neurons from 6-Hydroxydopamine-induced Caspase 3 Activation , 2003, Journal of Biological Chemistry.
[325] A. Lees,et al. Kufor Rakeb Disease: Autosomal recessive, levodopa‐responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia , 2005, Movement disorders : official journal of the Movement Disorder Society.
[326] Robert W. Taylor,et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease , 2006, Nature Genetics.
[327] P. Pollak,et al. Progressive encephalomyelitis with rigidity and myoclonus: Resolution after thymectomy , 2011, Neurology.
[328] A. López de Munain,et al. LRRK2 G2019S and R1441G mutations associated with Parkinson’s disease are common in the Basque Country, but relative prevalence is determined by ethnicity , 2009, neurogenetics.
[329] R. King,et al. Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology , 2009, Experimental Neurology.
[330] H. Payami,et al. Escaping Parkinson's disease: A neurologically healthy octogenarian with the LRRK2 G2019S mutation , 2005, Movement disorders : official journal of the Movement Disorder Society.
[331] J. Kaye,et al. Genetic anticipation in Parkinson's disease , 1995, Neurology.
[332] T. Foroud,et al. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8 , 2007, Neurology.
[333] A. Singleton,et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.
[334] E. Tolosa,et al. G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies , 2007, Journal of Neurology, Neurosurgery & Psychiatry.
[335] M. Beal,et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[336] S. Lincoln,et al. UCHL1 is associated with Parkinson's disease: A case-unaffected sibling and case-unrelated control study , 2005, Neuroscience Letters.
[337] C. Southan,et al. Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. , 2000, European journal of biochemistry.
[338] J. Haines,et al. A Genome‐wide Scan in an Amish Pedigree with Parkinsonism , 2008, Annals of human genetics.
[339] C. Tai,et al. Non-synonymous GIGYF2 variants in Parkinson’s disease from two Asian populations , 2009, Human Genetics.
[340] L. Chin,et al. Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. , 2010, Human molecular genetics.
[341] Hitoshi Takahashi,et al. An autopsy case of autosomal‐recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene , 2000, Movement disorders : official journal of the Movement Disorder Society.
[342] Vincenzo Bonifati,et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease , 2005, The Lancet.
[343] T. Dawson,et al. Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate* , 2006, Journal of Biological Chemistry.
[344] Jan Gründemann,et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase , 2006, Nature Genetics.
[345] D. Maraganore,et al. UCHL1 is a Parkinson's disease susceptibility gene , 2004, Annals of neurology.
[346] S. Tabrizi,et al. Correction: PINK1 Is Necessary for Long Term Survival and Mitochondrial Function in Human Dopaminergic Neurons , 2008, PLoS ONE.
[347] Philippe Amouyel,et al. α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[348] R. Nichols,et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. , 2007, The Biochemical journal.
[349] D. Godin,et al. Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.
[350] C. Gerloff,et al. Sensorimotor integration is abnormal in asymptomatic Parkin mutation carriers , 2007, Neurology.
[351] A. Felício,et al. PINK1 mutations in a Brazilian cohort of early‐onset Parkinson's disease patients , 2009, Movement disorders : official journal of the Movement Disorder Society.
[352] A. Brice,et al. A new complex homozygous large rearrangement of the PINK1 gene in a Sudanese family with early onset Parkinson’s disease , 2009, neurogenetics.
[353] C. Warren Olanow,et al. Altered Proteasomal Function in Sporadic Parkinson's Disease , 2003, Experimental Neurology.
[354] B. Jeon,et al. α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.
[355] D. Sulzer,et al. Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.
[356] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[357] Shinsei Minoshima,et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.
[358] B. Hyman,et al. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. , 2004, The Journal of biological chemistry.
[359] R. Scheller,et al. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[360] E. Tan,et al. Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore , 2008, Neurology.
[361] G. Dorn,et al. Nix Is Critical to Two Distinct Phases of Mitophagy, Reactive Oxygen Species-mediated Autophagy Induction and Parkin-Ubiquitin-p62-mediated Mitochondrial Priming* , 2010, The Journal of Biological Chemistry.
[362] S. Murayama,et al. [Autopsy case of SCA2 with Parkinsonian phenotype]. , 2010, Rinsho shinkeigaku = Clinical neurology.
[363] M. Farrer,et al. Analysis of LRRK2 functional domains in nondominant Parkinson disease , 2005, Neurology.
[364] Kostas Vekrellis,et al. Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells* , 2008, Journal of Biological Chemistry.
[365] Richard Paylor,et al. Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.
[366] B. Jeon,et al. The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System Atrophy , 2009, Journal of clinical neurology.
[367] K. Marder,et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease , 2007, Neurology.
[368] J. Langston,et al. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. , 2009, Neurotoxicology.
[369] R. Swerdlow,et al. Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.
[370] J. Trojanowski,et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[371] A. Dürr,et al. Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls , 2007, Journal of Medical Genetics.
[372] T. Foroud,et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset , 2009, Neurology.
[373] Kazuko Hasegawa,et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family , 2005, Annals of neurology.
[374] C. Ross,et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[375] Armin Giese,et al. Inhibition of mitochondrial fusion by α‐synuclein is rescued by PINK1, Parkin and DJ‐1 , 2010, The EMBO journal.
[376] Joachim Klose,et al. Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.
[377] Richard Wade-Martins,et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. , 2009, Human molecular genetics.
[378] P. S. St George-Hyslop,et al. Analysis of the glucocerebrosidase gene in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[379] S. Bardien,et al. Analysis of exon dosage using MLPA in South African Parkinson's disease patients , 2010, neurogenetics.
[380] D. Sulzer,et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. , 2000, Neuron.
[381] E. Sidransky. Gaucher disease: complexity in a "simple" disorder. , 2004, Molecular genetics and metabolism.
[382] R. Edwards,et al. Lipid rafts mediate the synaptic localization of alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[383] Mathias Toft,et al. MAPK‐pathway activity, Lrrk2 G2019S, and Parkinson's disease , 2007, Journal of neuroscience research.
[384] C A Ross,et al. Synphilin‐1 is present in Lewy bodies in Parkinson's disease , 2000, Annals of neurology.
[385] C. Klein,et al. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. , 2010, Cellular signalling.
[386] G. Schellenberg,et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients , 2007, Annals of neurology.
[387] J. Johnson,et al. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants , 2007, European journal of neurology.
[388] A. Sprenger,et al. Transcranial sonography findings in a large family with homozygous and heterozygous PINK1 mutations , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[389] A. Elbaz,et al. Update in the epidemiology of Parkinson's disease , 2008, Current opinion in neurology.
[390] Robert Edwards,et al. Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.
[391] D. James Surmeier,et al. ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease , 2007, Nature.
[392] J. Burgunder,et al. ATP13A2 G2236A variant is rare in patients with early-onset Parkinson's disease and familial Parkinson's disease from Mainland China. , 2010, Parkinsonism & related disorders.
[393] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[394] Jochen Klucken,et al. Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.
[395] A. Matouschek,et al. Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.
[396] P. Ragonese,et al. Identification of the novel D297fsX318 PINK1 mutation and phenotype variation in a family with early-onset Parkinson's disease. , 2008, Parkinsonism & related disorders.
[397] D. Hernandez,et al. Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: Evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease , 2005, Neuroscience Letters.
[398] M. Cookson,et al. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. , 2009, The American journal of pathology.
[399] A. Destée,et al. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. , 2009, Archives of neurology.
[400] D. Hernandez,et al. Characterization of PLA2G6 as a locus for dystonia‐parkinsonism , 2008, Annals of neurology.
[401] J. Noth,et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease , 2004, Neurology.
[402] C. Sampaio,et al. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal , 2007, Movement disorders : official journal of the Movement Disorder Society.
[403] Mark A. Wilson,et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[404] Y. Sohn,et al. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease , 2008, Neurogenetics.
[405] M. Russo,et al. The Parkinson-associated protein PINK1 interacts with Beclin1 and promotes autophagy , 2010, Cell Death and Differentiation.
[406] Marc Liesa,et al. Mitochondrial dynamics in mammalian health and disease. , 2009, Physiological reviews.
[407] C. Ross,et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.
[408] T. Dawson,et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase , 2007, Proceedings of the National Academy of Sciences.
[409] B. E. Staveley,et al. Mutant α-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease , 2006 .
[410] David S. Park,et al. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. , 2010, Human molecular genetics.
[411] D. Price,et al. Stabilization of α-Synuclein Protein with Aging and Familial Parkinson's Disease-Linked A53T Mutation , 2004, The Journal of Neuroscience.
[412] YongSung Kim,et al. PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. , 2008, Biochemical and biophysical research communications.
[413] E. Waxman,et al. Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein , 2008, Journal of neuropathology and experimental neurology.
[414] A. Lang,et al. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. , 2001, Human molecular genetics.
[415] M. Cookson,et al. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. , 2007, Biochemical and biophysical research communications.
[416] A. Barzilai,et al. The Involvement of p53 in Dopamine-Induced Apoptosis of Cerebellar Granule Neurons and Leukemic Cells Overexpressing p53 , 1999, Cellular and Molecular Neurobiology.
[417] T. Nägele,et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. , 2005, Brain : a journal of neurology.
[418] Homayoun Sadeghi,et al. A clinic‐based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson's disease patients , 2009, Movement disorders : official journal of the Movement Disorder Society.
[419] K. Marder,et al. Association of glucocerebrosidase mutations with dementia with lewy bodies. , 2009, Archives of neurology.
[420] P. Heutink,et al. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[421] S. Paek,et al. Spinocerebellar ataxia type 17 mutation as a causative and susceptibility gene in parkinsonism , 2009, Neurology.
[422] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[423] E. Masliah,et al. Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease. , 2003, The Journal of biological chemistry.
[424] C. van Broeckhoven,et al. Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population , 2009, Human mutation.
[425] T. Kondo,et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q , 1998, Neurology.
[426] T. Nagatsu. [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.
[427] Donato A Di Monte,et al. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.
[428] J. Perlmutter,et al. Association of α-synuclein gene haplotypes with Parkinson's disease , 2007 .
[429] P. Verstreken,et al. Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function , 2009, EMBO molecular medicine.
[430] Vincenzo Bonifati,et al. Early‐onset Parkinson's disease caused by a compound heterozygous DJ‐1 mutation , 2003, Annals of neurology.
[431] N. Hattori,et al. Diverse Effects of Pathogenic Mutations of Parkin That Catalyze Multiple Monoubiquitylation in Vitro* , 2006, Journal of Biological Chemistry.
[432] R. Benecke,et al. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. , 1993, Brain : a journal of neurology.
[433] J. Jankovic,et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. , 2006, Archives of neurology.
[434] S. Tsuji,et al. Novel mutations, pseudo‐dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism , 2000, Annals of neurology.
[435] M. Vidailhet,et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. , 2011, Human molecular genetics.
[436] A. Durr,et al. The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson’s disease in European populations , 2005, Journal of Medical Genetics.
[437] S. Lindquist,et al. α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.
[438] E. Sidransky,et al. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA) , 2008, Human mutation.
[439] C. Marsden,et al. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.
[440] M. Farrer,et al. alpha-Synuclein and Parkinson disease susceptibility. , 2007, Neurology.
[441] J. Downward,et al. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1 , 2007, Nature Cell Biology.
[442] Yi Zhao,et al. LRRK2 R1628P increases risk of Parkinson’s disease: replication evidence , 2008, Human Genetics.
[443] P. Lockhart,et al. Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.
[444] M. Glicksman,et al. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. , 2010, Biochemistry.
[445] Daniel R. Scoles,et al. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. , 2003, Human molecular genetics.
[446] T. Iwatsubo. [alpha-Synuclein and familial Parkinson's disease]. , 1999, No to shinkei = Brain and nerve.
[447] M. Beal,et al. PINK1 Defect Causes Mitochondrial Dysfunction, Proteasomal Deficit and α-Synuclein Aggregation in Cell Culture Models of Parkinson's Disease , 2009, PloS one.
[448] A. Whitworth,et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss , 2009, Nature Neuroscience.
[449] M. Farrer,et al. α-Synuclein and Parkinson disease susceptibility , 2007, Neurology.
[450] He-Jin Lee,et al. Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway , 2004, The Journal of Neuroscience.
[451] J. Lee,et al. Rhomboid-7 and HtrA 2 / Omi act in a common pathway with the Parkinson ’ s disease factors Pink 1 and Parkin , 2022 .
[452] M. Cookson,et al. Parkin-mediated ubiquitination regulates phospholipase C-γ1 , 2008, Journal of cellular and molecular medicine.
[453] J. Nutt,et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. , 2006, American journal of human genetics.
[454] Peter T. Lansbury,et al. Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.
[455] N. Wood,et al. PINK1 (PARK6) associated Parkinson disease in Ireland , 2004, Neurology.
[456] Sonja W. Scholz,et al. Parkin and PINK1 mutations in early-onset Parkinson’s disease: comprehensive screening in publicly available cases and control , 2009, Journal of Medical Genetics.
[457] Daniel Sage,et al. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. , 2008, Human molecular genetics.
[458] Colin A. Johnson,et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron , 2006, Nature Genetics.
[459] R A Crowther,et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[460] A. Brookes,et al. The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls. , 2001, Parkinsonism & related disorders.
[461] J. Nutt,et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease , 2010, Nature Genetics.
[462] J. Ridet,et al. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[463] A. Destée,et al. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. , 2007, Archives of neurology.
[464] M. Cookson,et al. Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling , 2009, The FEBS journal.
[465] K. Marder,et al. Distribution, type, and origin of Parkin mutations: Review and case studies , 2004, Movement disorders : official journal of the Movement Disorder Society.
[466] A. Dürr,et al. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. , 2005, American journal of human genetics.
[467] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[468] C. Chien,et al. The utility F-box for protein destruction , 2008, Cellular and Molecular Life Sciences.
[469] Y. Agid,et al. Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. , 2003, Archives of neurology.
[470] P. Lansbury,et al. The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.
[471] Takashi Uehara,et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[472] P. Lansbury,et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.
[473] M. Ehlers,et al. Pruning and loss of excitatory synapses by the parkin ubiquitin ligase , 2008, Proceedings of the National Academy of Sciences.
[474] N. Bonini,et al. DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function , 2010, Proceedings of the National Academy of Sciences.
[475] PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1 , 2007, PLoS biology.
[476] A. Sidhu,et al. Does α‐synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004 .
[477] T. Meitinger,et al. Multiple regions of α‐synuclein are associated with Parkinson's disease , 2005, Annals of neurology.
[478] J. C. Greene,et al. Immune responses , 2004 .
[479] B. Ghetti,et al. Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.
[480] T. Dawson,et al. Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons , 2009, Molecular Neurodegeneration.
[481] N. Hattori,et al. A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype , 2009, neurogenetics.
[482] M. Farrer,et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese , 2000, Neurology.
[483] A. Samii,et al. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease , 2006, Neurology.
[484] B. E. Staveley,et al. parkin counteracts symptoms in a Drosophila model of Parkinson's disease , 2004, BMC Neuroscience.
[485] M. Farrer,et al. ATP13A2 variability in Parkinson disease , 2009, Human mutation.
[486] M. Beal,et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[487] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[488] David S. Park,et al. BAG5 Inhibits Parkin and Enhances Dopaminergic Neuron Degeneration , 2004, Neuron.
[489] A. Singleton,et al. Association of α‐synuclein Rep1 polymorphism and Parkinson's disease: Influence of Rep1 on age at onset , 2006, Movement disorders : official journal of the Movement Disorder Society.
[490] C. Marsden,et al. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. , 1992, Annals of neurology.
[491] R. Barker,et al. A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein. , 2005, Journal of neurology, neurosurgery, and psychiatry.
[492] Jeffrey H Kordower,et al. Proteasome inhibition and Parkinson's disease modeling , 2006, Annals of neurology.
[493] R. Szargel,et al. Monoubiquitylation of α-Synuclein by Seven in Absentia Homolog (SIAH) Promotes Its Aggregation in Dopaminergic Cells* , 2008, Journal of Biological Chemistry.
[494] J. Troncoso,et al. S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function , 2004, Science.
[495] M. Mena,et al. Differential effects of l‐DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal‐enriched cultures from parkin knockout and wild‐type mice , 2005, Journal of neurochemistry.
[496] V. Mylius,et al. The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson’s disease , 2008, European journal of neurology.
[497] O. Combarros,et al. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease , 2006, Neuroscience Letters.
[498] E. Katunina,et al. [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
[499] M. Farrer,et al. Genomic investigation of α‐synuclein multiplication and parkinsonism , 2008, Annals of neurology.
[500] P. Silburn,et al. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. , 2009, Parkinsonism & related disorders.
[501] F. Giorgino,et al. Two Novel Proteins That Are Linked to Insulin-like Growth Factor (IGF-I) Receptors by the Grb10 Adapter and Modulate IGF-I Signaling* , 2003, Journal of Biological Chemistry.
[502] A. Schapira,et al. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. , 2010, Human molecular genetics.
[503] V. Nair. Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson’s disease , 2006, Apoptosis.
[504] A. Letai,et al. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. , 2009, Human molecular genetics.
[505] J. Cooper,et al. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease , 1998, Annals of neurology.
[506] R. Schwab,et al. COHORT ANALYSIS OF PARKINSON'S SYNDROME: EVIDENCE FOR A SINGLE ETIOLOGY RELATED TO SUBCLINICAL INFECTION ABOUT 1920. , 1963, Journal of chronic diseases.
[507] A. Bentivoglio,et al. GIGYF2 variants are not associated with Parkinson's disease in Italy , 2009, Movement disorders : official journal of the Movement Disorder Society.
[508] J. Holton,et al. PINK1 protein in normal human brain and Parkinson's disease. , 2006, Brain : a journal of neurology.
[509] K. Jellinger,et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.
[510] W. Xia,et al. Dimerization of Parkinson's disease-causing DJ-1 and formation of high molecular weight complexes in human brain , 2004, Molecular and Cellular Neuroscience.
[511] C. Ross,et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.
[512] Jian Feng,et al. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. , 2004, Human molecular genetics.
[513] J. Cooper,et al. Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells , 2009, PloS one.
[514] K. Xia,et al. Novel GIGYF2 gene variants in patients with Parkinson's disease in Chinese population , 2010, Neuroscience Letters.
[515] H. Budka,et al. Accumulation of HtrA2/Omi in Neuronal and Glial Inclusions in Brains With &agr;-Synucleinopathies , 2008, Journal of neuropathology and experimental neurology.
[516] Douglas C. Miller,et al. A large kindred with autosomal dominant Parkinson's disease , 1990, Annals of neurology.
[517] C. Waters,et al. Autosomal dominant Lewy body parkinsonism in a four‐generation family , 1994, Annals of neurology.
[518] David S. Park,et al. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. , 2009, Human molecular genetics.
[519] A. Quattrone,et al. LRRK2 G6055A mutation in Italian patients with familial or sporadic Parkinson’s disease , 2007, Clinical genetics.
[520] Peter T. Lansbury,et al. Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.
[521] C. Chu,et al. Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells , 2008, Journal of neurochemistry.
[522] F. Lee,et al. Parkin Disrupts the α-Synuclein/Dopamine Transporter Interaction: Consequences Toward Dopamine-induced Toxicity , 2007, Journal of Molecular Neuroscience.
[523] Min Liu,et al. Parkin Ubiquitinates Drp1 for Proteasome-dependent Degradation , 2011, The Journal of Biological Chemistry.
[524] G. Halliday,et al. An inflammatory review of Parkinson’s disease , 2002, Progress in Neurobiology.
[525] Sonja W. Scholz,et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data , 2006, The Lancet Neurology.
[526] D. Rubinsztein,et al. Loss of PINK1 Function Affects Development and Results in Neurodegeneration in Zebrafish , 2008, The Journal of Neuroscience.
[527] C Büchel,et al. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia , 2007, Neurology.
[528] Y. Itoyama,et al. Serine 129 Phosphorylation of α-Synuclein Induces Unfolded Protein Response-mediated Cell Death* , 2008, Journal of Biological Chemistry.
[529] J. Allman,et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. , 2004, Molecular genetics and metabolism.
[530] J. Burgunder,et al. LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han‐Chinese from mainland China , 2009, Movement disorders : official journal of the Movement Disorder Society.
[531] P. Pollak,et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. , 2006, The New England journal of medicine.
[532] Janel O. Johnson,et al. Comprehensive Screening of a North American Parkinson’s Disease Cohort for LRRK2 Mutation , 2007, Neurodegenerative Diseases.
[533] Y. Agid,et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. , 2003, Brain : a journal of neurology.
[534] T. Zhang,et al. The GIGYF2 variants are not associated with Parkinson's disease in the mainland Chinese population. , 2010, Parkinsonism & related disorders.
[535] A Dürr,et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. , 2004, Lancet.
[536] J. Cappell,et al. Tiagabine-induced nonconvulsive status epilepticus in an adolescent without epilepsy , 2006, Neurology.
[537] A. Singleton,et al. Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. , 2008, Human molecular genetics.
[538] A. Brice,et al. Neurophysiological evidence of corticospinal tract abnormality in patients with Parkin mutations , 2006, Journal of Neurology.
[539] P. Jenner,et al. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats , 2006, Annals of neurology.
[540] G. Tocchini-Valentini,et al. Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[541] J. Epplen,et al. The LRRK2 gene in Parkinson’s disease: mutation screening in patients from Germany , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[542] S. Papapetropoulos,et al. Clinical characteristics of the alpha‐synuclein mutation (G209A)‐associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece , 2003, European journal of neurology.
[543] M. Farrer,et al. A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. , 2009, Parkinsonism & related disorders.
[544] A. Singleton,et al. Parkinson's Disease and Low Frequency Alleles Found Together Throughout LRRK2 , 2009, Annals of human genetics.
[545] T. Iwatsubo,et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[546] Mohamad Saad,et al. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. , 2011, Human molecular genetics.
[547] Hongjun Song,et al. Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death , 2005, The Journal of Neuroscience.
[548] E. Hirsch,et al. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. , 2003, Human molecular genetics.
[549] Sonja Hess,et al. Broad activation of the ubiquitin–proteasome system by Parkin is critical for mitophagy , 2011, Human molecular genetics.
[550] Thorsten Schmidt,et al. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis , 2004, The Lancet Neurology.
[551] P. Damier,et al. Follow-up study of the GIGYF2 gene in French families with Parkinson's disease , 2010, Neurobiology of Aging.
[552] M. Farrer,et al. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. , 2007, Parkinsonism & related disorders.
[553] H. Liu. Alpha-synuclein and Parkinson disease* , 2007 .
[554] A. Sidhu,et al. Modulation of dopamine transporter function by α‐synuclein is altered by impairment of cell adhesion and by induction of oxidative stress , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[555] Mark A. Wilson,et al. Formation of a Stabilized Cysteine Sulfinic Acid Is Critical for the Mitochondrial Function of the Parkinsonism Protein DJ-1* , 2009, Journal of Biological Chemistry.
[556] Cao Li,et al. The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease. , 2007, Movement disorders : official journal of the Movement Disorder Society.
[557] E. Schon,et al. The kinase domain of mitochondrial PINK1 faces the cytoplasm , 2008, Proceedings of the National Academy of Sciences.
[558] J. Stockman. Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .
[559] P. Lockhart,et al. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function , 2004, Journal of Medical Genetics.
[560] A. Pisani,et al. Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin , 2009, Experimental Neurology.
[561] Normand L. Frigon,et al. Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System*S⃞ , 2009, Journal of Biological Chemistry.
[562] K. Lim,et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.
[563] N. Hattori,et al. Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification , 2000, Brain and Development.
[564] M. Umeda,et al. Proteasome Inhibitor Does Not Enhance MPTP Neurotoxicity in Mice , 2008, Cellular and Molecular Neurobiology.
[565] Yusuke Nakamura,et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.
[566] J. Trojanowski,et al. Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration , 2008, The Journal of Neuroscience.
[567] Nir Giladi,et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset , 2008, Neurology.
[568] M. Farrer,et al. Multiple alpha‐synuclein gene polymorphisms are associated with Parkinson’s disease in a Norwegian population , 2008, Acta neurologica Scandinavica.
[569] M. Ban,et al. Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease , 2007 .
[570] N. Hattori,et al. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism , 2005, Neurology.
[571] M. Polymeropoulos,et al. Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23 , 1996, Science.
[572] R. Hilker,et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers , 2005, Annals of neurology.
[573] R. Takahashi,et al. Phosphorylation of 4E‐BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila , 2008, The EMBO journal.
[574] D. Dickson,et al. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson’s disease , 2008, Acta Neuropathologica.
[575] N. Brüggemann,et al. Frequency of heterozygous Parkin mutations in healthy subjects: need for careful prospective follow-up examination of mutation carriers. , 2009, Parkinsonism & related disorders.
[576] David W. Miller,et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.
[577] N. Hattori,et al. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin‐like domain , 2003, EMBO reports.
[578] R. J. Kelleher,et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice , 2010, Proceedings of the National Academy of Sciences.
[579] J. Trojanowski,et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. , 2002, Acta neuropathologica.
[580] E. Beutler,et al. Hematologically important mutations: Gaucher disease. , 2005, Blood cells, molecules & diseases.
[581] Steven P Gygi,et al. Certain Pairs of Ubiquitin-conjugating Enzymes (E2s) and Ubiquitin-Protein Ligases (E3s) Synthesize Nondegradable Forked Ubiquitin Chains Containing All Possible Isopeptide Linkages* , 2007, Journal of Biological Chemistry.
[582] R. Palmiter,et al. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6 , 2007, The Journal of cell biology.
[583] P. Kempster,et al. A new look at James Parkinson's Essay on the Shaking Palsy , 2007, Neurology.
[584] D. Elstein,et al. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2005, The New England journal of medicine.
[585] A. Torroni,et al. Mitochondrial oxidative phosphorylation defects in parkinson's disease , 1991, Annals of neurology.
[586] A. Lang,et al. Deciphering the role of heterozygous mutations in genes associated with parkinsonism , 2007, The Lancet Neurology.
[587] W. Oertel,et al. Alpha‐synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients , 2005, Movement disorders : official journal of the Movement Disorder Society.
[588] J. Perlmutter,et al. Association of alpha-synuclein gene haplotypes with Parkinson's disease. , 2007, Parkinsonism & Related Disorders.
[589] F. Brancati,et al. Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum , 2007, Human mutation.
[590] Timothy Lynch,et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.
[591] N. Hattori,et al. Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. , 2003, The Journal of biological chemistry.
[592] R. Youle,et al. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy , 2008, The Journal of cell biology.
[593] A. Brice,et al. Parkin occurs in a stable, non-covalent, ∼110-kDa complex in brain , 2008, The European journal of neuroscience.
[594] Jie Shen,et al. Absence of nigral degeneration in aged parkin/DJ‐1/PINK1 triple knockout mice , 2009, Journal of neurochemistry.
[595] D. Price,et al. Parkinson's Disease α-Synuclein Transgenic Mice Develop Neuronal Mitochondrial Degeneration and Cell Death , 2006, The Journal of Neuroscience.
[596] D. D. Di Monte. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.
[597] Bertram Müller-Myhsok,et al. Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease , 2005, Neuroscience Letters.
[598] E. Valente,et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. , 2005, Human molecular genetics.
[599] Wolfgang Wurst,et al. Loss of Parkin or PINK1 Function Increases Drp1-dependent Mitochondrial Fragmentation* , 2009, The Journal of Biological Chemistry.
[600] Gianluigi Forloni,et al. DJ-1 Modulates α-Synuclein Aggregation State in a Cellular Model of Oxidative Stress: Relevance for Parkinson's Disease and Involvement of HSP70 , 2008, PloS one.
[601] K. Wada,et al. Aberrant Interaction between Parkinson Disease-associated Mutant UCH-L1 and the Lysosomal Receptor for Chaperone-mediated Autophagy* , 2008, Journal of Biological Chemistry.
[602] A. Singleton,et al. Analysis of Nigerians with Apparently Sporadic Parkinson Disease for Mutations in LRRK2, PRKN and ATXN3 , 2008, PloS one.
[603] A. Abeliovich,et al. DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation , 2004, PLoS biology.
[604] Georg Auburger,et al. The ubiquitin pathway in Parkinson's disease , 1998, Nature.
[605] Y. Agid,et al. Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism , 2003, Neurology.
[606] C. Geula,et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons , 2006, Nature Genetics.
[607] P. Lansbury,et al. Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein* , 2008, Journal of Biological Chemistry.
[608] M. Farrer,et al. Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. , 2009, Parkinsonism & related disorders.
[609] A Hofman,et al. Prevalence of Parkinson's disease in the elderly , 1995, Neurology.
[610] J. C. Greene,et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[611] L. Seeberger,et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease , 2003, Neurology.
[612] Jurg Ott,et al. Genome‐wide autozygosity mapping in human populations , 2009, Genetic epidemiology.
[613] Tom A. Rapoport,et al. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol , 2001, Nature.
[614] R A Crowther,et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. , 1998, Neuroscience letters.
[615] Karl Herholz,et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans , 2002, Neuroscience Letters.
[616] A. Abeliovich,et al. The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology , 2006, Neuron.
[617] Ying Wang,et al. Lack of association between ATP13A2 Ala746Thr variant and Parkinson's disease in Han population of mainland China , 2010, Neuroscience Letters.
[618] D. Maraganore,et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.
[619] J. Xie,et al. Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled , 2006, The Journal of Neuroscience.
[620] D. Benson,et al. Alzheimer's disease and Parkinson's disease , 1988, Neurology.
[621] W. Hwu,et al. Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations. , 2006, Blood cells, molecules & diseases.
[622] J. Y. Kim,et al. Does hereditary hemochromatosis influence the age of onset of Huntington's disease? , 2010, Movement disorders : official journal of the Movement Disorder Society.
[623] He-Jin Lee,et al. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[624] J. Jankovic,et al. Lrrk2 R1441G-related Parkinson’s disease: evidence of a common founding event in the seventh century in Northern Spain , 2009, neurogenetics.
[625] M. Cookson,et al. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase , 2008, Proceedings of the National Academy of Sciences.
[626] Philippe Amouyel,et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.
[627] K. Sobczak,et al. CAG Repeats Containing CAA Interruptions Form Branched Hairpin Structures in Spinocerebellar Ataxia Type 2 Transcripts* , 2005, Journal of Biological Chemistry.
[628] M. Farrer,et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. , 2007, Parkinsonism & related disorders.
[629] A. Singleton,et al. Lack of replication of association between GIGYF2 variants and Parkinson disease. , 2008, Human molecular genetics.
[630] A. Destée,et al. Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson’s disease , 2009, Journal of Medical Genetics.
[631] J. Feldon,et al. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[632] R. Takahashi,et al. Pael‐R is accumulated in Lewy bodies of Parkinson's disease , 2004, Annals of neurology.
[633] T. Dawson,et al. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[634] R. Ramsay,et al. Mechanism of the neurotoxicity of MPTP , 1990, FEBS letters.
[635] G. Lopez,et al. The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism , 2009, Movement disorders : official journal of the Movement Disorder Society.
[636] A. Schapira. Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.
[637] Yi Zhao,et al. Genetic analysis of DJ-1 in a cohort Parkinson’s disease patients of different ethnicity , 2004, Neuroscience Letters.
[638] T. Gillis,et al. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. , 2006, Archives of neurology.
[639] R. Marconi,et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease , 2007, Neurology.
[640] C. Culmsee,et al. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[641] D. Cordato,et al. Genetics and Parkinson’s disease , 2004, Journal of Clinical Neuroscience.
[642] M. Farrer,et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries , 2006, Movement disorders : official journal of the Movement Disorder Society.
[643] A. Whitworth,et al. PINK1 cleavage at position A103 by the mitochondrial protease PARL , 2010, Human molecular genetics.
[644] Nicholas W Wood,et al. A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.
[645] A. Varrone,et al. PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism , 2006, Movement disorders : official journal of the Movement Disorder Society.
[646] M. Farrer,et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication , 2007, Neurology.
[647] J Q Trojanowski,et al. A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.
[648] N. Quinn,et al. The role of pathogenic DJ‐1 mutations in Parkinson's disease , 2003, Annals of neurology.
[649] O. Riess,et al. Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early‐onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients , 2004, Human mutation.
[650] Changan Jiang,et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.
[651] Akihiko Iwai,et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.
[652] K. McNaught,et al. Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.
[653] K. Xia,et al. Analysis of SCA2 and SCA3/MJD repeats in Parkinson's disease in mainland China: Genetic, clinical, and positron emission tomography findings , 2009, Movement disorders : official journal of the Movement Disorder Society.
[654] S. Murayama,et al. Alpha‐synucleinopathy is associated with spinocerebellar ataxia type 2 with Parkinsonism , 2008 .
[655] David F. Clayton,et al. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.
[656] U. Muthane,et al. Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients , 2006, Neuroscience Letters.
[657] M. Farrer,et al. Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population , 2006, Neurology.
[658] Matti Pirinen,et al. Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21 , 2010, Human molecular genetics.
[659] J. Trojanowski,et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.
[660] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[661] D. Eliezer,et al. Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.
[662] I. Guella,et al. Mutational screening and zebrafish functional analysis of GIGYF2 as a Parkinson-disease gene , 2009, Neurobiology of Aging.
[663] B. Oostra,et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan , 2006, Neurogenetics.
[664] N. Mizushima,et al. Parkin Mediates Proteasome-dependent Protein Degradation and Rupture of the Outer Mitochondrial Membrane*♦ , 2011, The Journal of Biological Chemistry.
[665] C. Fusco,et al. Characterization of a Novel Human Serine Protease That Has Extensive Homology to Bacterial Heat Shock Endoprotease HtrA and Is Regulated by Kidney Ischemia* , 2000, The Journal of Biological Chemistry.
[666] R. Ridley,et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. , 2007, Brain : a journal of neurology.
[667] H. Niznik,et al. Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[668] A. Lees,et al. A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.
[669] J. Trojanowski,et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders , 2006, Neurology.
[670] E. Bertini,et al. Neurodegeneration associated with genetic defects in phospholipase A2 , 2008, Neurology.
[671] H. Inoko,et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. , 2006, Human molecular genetics.
[672] A. Lang,et al. Genetic association study of PINK1 coding polymorphisms in Parkinson's disease , 2004, Neuroscience Letters.
[673] Nir Giladi,et al. Ashkenazi Parkinson’s disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries , 2009, neurogenetics.
[674] Shawn K. Westaway,et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome , 2001, Nature Genetics.
[675] Nigel J. Cairns,et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.
[676] Nikolaus R. McFarland,et al. &agr;-Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal Toxicity in a Rat Model of Parkinson Disease , 2009, Journal of neuropathology and experimental neurology.
[677] P. Lockhart,et al. Functional association of the parkin gene promoter with idiopathic Parkinson's disease. , 2002, Human molecular genetics.
[678] R. Krüger,et al. Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease. , 2003, Brain : a journal of neurology.
[679] D. Perl,et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.
[680] Santiago Canals,et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. , 2003, Human molecular genetics.
[681] T. Noda,et al. A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation , 2009, Nature Cell Biology.
[682] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[683] M. Farrer,et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients , 2005, Neuroscience Letters.
[684] L. Seeberger,et al. Significant linkage of Parkinson disease to chromosome 2q36-37. , 2003, American journal of human genetics.
[685] M. Cookson,et al. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. , 2009, Biochemistry.
[686] R. Youle,et al. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin , 2010, The Journal of cell biology.
[687] A. Destée,et al. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? , 2007, Neurology.
[688] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[689] Rachel Levy,et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. , 2006, American journal of human genetics.
[690] G. Mardon,et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress , 2004, Development.
[691] Y. Hong,et al. Parkin Suppresses c-Jun N-terminal kinase-induced cell death via transriptional regulation in Drosophila , 2010, Molecules and cells.
[692] Mostafa Ronaghi,et al. Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson disease , 2008, Human mutation.
[693] N. Wood,et al. Mitochondrial function and morphology are impaired in parkin‐mutant fibroblasts , 2008, Annals of neurology.
[694] E. Masliah,et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[695] K. Gwinn‐Hardy,et al. Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease , 2004, Clinical genetics.
[696] Philippe Vernier,et al. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[697] P. Allen,et al. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle , 1995, Neurology.
[698] E. Tolosa,et al. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. , 2006, Archives of neurology.
[699] R. Nicoll,et al. Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.
[700] Ying Wang,et al. GIGYF2 Asn56Ser mutation is rare in Chinese Parkinson's disease patients , 2009, Neuroscience Letters.
[701] Y. Agid,et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease , 2005, Annals of neurology.
[702] Nobutaka Hattori,et al. Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.
[703] Reidun Torp,et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. , 2005, Human molecular genetics.
[704] T. Hirokawa,et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. , 2003, Biochemical and biophysical research communications.
[705] S. Karlsson,et al. Murine models of acute neuronopathic Gaucher disease , 2007, Proceedings of the National Academy of Sciences.
[706] M. Feany,et al. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. , 2005, Nature neuroscience.
[707] A. Antonini,et al. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation , 2007, Movement disorders : official journal of the Movement Disorder Society.
[708] A. Dürr,et al. Deletion of the parkin and PACRG gene promoter in early‐onset parkinsonism , 2007, Human mutation.
[709] B. Oostra,et al. LRRK2 MUTATION ANALYSIS IN PARKINSON DISEASE FAMILIES WITH EVIDENCE OF LINKAGE TO PARK8 , 2008, Neurology.
[710] A. Brice,et al. Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations , 2001, Neurology.
[711] M. Farrer,et al. Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p , 2000, Acta Neuropathologica.
[712] Irene Litvan,et al. Lrrk2 and Lewy body disease , 2006, Annals of neurology.
[713] C. Ross,et al. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[714] C. Ki,et al. The Ala53Thr mutation in the alpha-synuclein gene in a Korean family with Parkinson disease. , 2007, Clinical genetics.
[715] D. Selkoe,et al. Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. , 2008, Human molecular genetics.
[716] L. Serpell,et al. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[717] C. Marsden,et al. Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.
[718] T. Chase,et al. Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.
[719] M. Breteler,et al. Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.
[720] K. Marder,et al. Case-control study of the parkin gene in early-onset Parkinson disease. , 2006, Archives of neurology.
[721] S. Tsuji,et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.
[722] D. Hernandez,et al. Lewy bodies and parkinsonism in families with parkin mutations , 2001, Annals of neurology.
[723] T. Dawson,et al. Parkin mediates the degradation‐independent ubiquitination of Hsp70 , 2008, Journal of neurochemistry.
[724] C. Chu. A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease. , 2010, Human molecular genetics.
[725] C. Ross,et al. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[726] Y. Imai,et al. Parkin Suppresses Unfolded Protein Stress-induced Cell Death through Its E3 Ubiquitin-protein Ligase Activity* , 2000, The Journal of Biological Chemistry.
[727] P. Matthews,et al. LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study , 2008, The Lancet Neurology.
[728] C. Ross,et al. α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.
[729] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[730] John Q. Trojanowski,et al. Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.
[731] N. Hattori,et al. PARK9-LINKED PARKINSONISM IN EASTERN ASIA: MUTATION DETECTION IN ATP13A2 AND CLINICAL PHENOTYPE , 2008, Neurology.
[732] A. Dürr,et al. Clinical and molecular advances in autosomal dominant cerebellar ataxias: from genotype to phenotype and physiopathology , 2000, European Journal of Human Genetics.
[733] A. Singleton,et al. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls , 2008, Human mutation.
[734] P. Lockhart,et al. Parkin genetics: one model for Parkinson's disease. , 2004, Human molecular genetics.
[735] A. Björklund,et al. Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.
[736] H. Niznik,et al. Direct binding and functional coupling of α‐synuclein to the dopamine transporters accelerate dopamine‐induced apoptosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[737] M. Farrer,et al. Familial genes in sporadic disease: Common variants of α-synuclein gene associate with Parkinson's disease , 2007, Mechanisms of Ageing and Development.
[738] P. Kapahi,et al. Loss-of-Function Analysis Suggests That Omi/HtrA2 Is Not an Essential Component of the pink1/parkin Pathway In Vivo , 2008, The Journal of Neuroscience.
[739] Aldo Quattrone,et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.
[740] V. Mok,et al. LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson’s disease compared to late-onset patients , 2008, Journal of Neural Transmission.
[741] Min Liu,et al. Parkin Regulates Eg5 Expression by Hsp70 Ubiquitination-dependent Inactivation of c-Jun NH2-terminal Kinase* , 2008, Journal of Biological Chemistry.
[742] T. Gasser,et al. Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families , 2007, Neuroscience Letters.
[743] Sunhong Kim,et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.
[744] Christian Haass,et al. Pathological properties of the Parkinson’s disease-associated protein DJ-1 in α-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick’s disease , 2004, Acta Neuropathologica.
[745] J. Kordower,et al. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? , 2007, Neurobiology of Disease.
[746] J. Nutt,et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[747] R. Krüger,et al. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7) , 2004, Human mutation.
[748] D. Eliezer,et al. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. , 2004, Biochemistry.
[749] L. Scorrano,et al. Mitofusin 2 tethers endoplasmic reticulum to mitochondria , 2008, Nature.
[750] S. Minoshima,et al. Immunohistochemical and subcellular localization of parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients , 1999, Annals of neurology.
[751] M. Farrer,et al. Genetic variation of Omi/HtrA2 and Parkinson's disease. , 2008, Parkinsonism & related disorders.
[752] R. Youle,et al. Parkin-induced mitophagy in the pathogenesis of Parkinson disease , 2009, Autophagy.
[753] David W. Miller,et al. L166P Mutant DJ-1, Causative for Recessive Parkinson's Disease, Is Degraded through the Ubiquitin-Proteasome System* , 2003, Journal of Biological Chemistry.
[754] R. Palmiter,et al. Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age* , 2003, Journal of Biological Chemistry.
[755] Bernardino Ghetti,et al. Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders , 2006, The Journal of Neuroscience.
[756] S. Srinivasula,et al. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice , 2003, Nature.
[757] A. Antonini,et al. alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. , 2010, Parkinsonism & related disorders.
[758] N. Hattori,et al. Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population , 2007, Neuroreport.